Tiotropium reduces the risk of exacerbations irrespective of previous use of inhaled anticholinergics in placebo-controlled clinical trials

C. Cooper, M. Decramer, I. Leimer, S. Kesten (Los Angeles, CA, United States Of America; Leuven, Belgium; Ingelheim, Germany)

Source: Annual Congress 2008 - Pathogenesis and treatment of asthma and COPD
Session: Pathogenesis and treatment of asthma and COPD
Session type: Thematic Poster Session
Number: 3608
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
C. Cooper, M. Decramer, I. Leimer, S. Kesten (Los Angeles, CA, United States Of America; Leuven, Belgium; Ingelheim, Germany). Tiotropium reduces the risk of exacerbations irrespective of previous use of inhaled anticholinergics in placebo-controlled clinical trials. Eur Respir J 2008; 32: Suppl. 52, 3608

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Efficacy and safety of as-needed corticosteroid plus fast or short-acting beta-agonists monotherapy in patients with mild asthma: a meta-analysis of randomised controlled trials.
Source: Virtual Congress 2020 – Inhaled corticosteroids and bronchodilator studies in asthma
Year: 2020

The effect of low-dose corticosteroids and theophylline on the risk of acute exacerbations of COPD: the TASCS randomised controlled trial
Source: Eur Respir J, 57 (6) 2003338; 10.1183/13993003.03338-2020
Year: 2021



Description of a randomised controlled trial of inhaled corticosteroid/fast-onset LABA reliever therapy in mild asthma
Source: Eur Respir J 2016; 47: 981-984
Year: 2016


How to reduce COPD exacerbations with inhaled drugs? A pooled analysis of randomized trials
Source: Annual Congress 2008 - Organisation of care and management of COPD
Year: 2008

Omalizumab in patients with moderate-to-severe persistent asthma poorly controlled on high-dose inhaled corticosteroids and long-acting beta-agonists: Results of a phase IIIb randomized controlled trial
Source: Annual Congress 2010 - Aspects of severe asthma
Year: 2010


A randomised controlled trial to investigate the optimal dose and effect of salbutamol for the treatment of acute exacerbations of COPD
Source: Eur Respir J 2002; 20: Suppl. 38, 244s
Year: 2002

Safety of long-acting β-agonist (LABA) withdrawal in patients in two clinical asthma trials
Source: Annual Congress 2012 - Different ways to phenotype asthma
Year: 2012



Cardioselective beta-blockers are not only safe in patients with COPD, but may also improve the responsibility of FEV1 to beta-agonist: A meta-analysis of randomized controlled double-blinded trials
Source: Annual Congress 2012 - Pharmacological and non-pharmacological management of COPD
Year: 2012

A multi-centre doubleblind randomised study examining the clinical outcome of treatment of the first asthma exacerbation with salmeterol xinafoate/fluticasone propionate combination product versus prednisolone
Source: Eur Respir J 2003; 22: Suppl. 45, 287s
Year: 2003

Maintenance and reliever combination budesonide/formoterol therapy in asthma patients at risk of severe exacerbations: A randomised controlled trial
Source: Annual Congress 2013 –LAMA, LABA, ICS and their combinations for the treatment of asthma and COPD
Year: 2013


Evaluation of ICS/LABA combination therapy on respiratory function in patients with asthma: Open-label, randomized, cross-over trial.
Source: International Congress 2018 – New developments in the treatment of asthma
Year: 2018


Lower incidence of asthma exacerbations with FENO-guided anti-inflammatory treatment: A randomised controlled trial
Source: Annual Congress 2012 - Effectiveness of respiratory disease management in primary care
Year: 2012


Using placebo-controlled trials to define predictors of future exacerbations in severe asthma patients
Source: Eur Respir J, 58 (6) 2101702; 10.1183/13993003.01702-2021
Year: 2021



Effects of combined therapy with nebulized b2-agonist and anticholinergic in severe exacerbation of chronic obstructive pulmonary disease. Randomized controlled trial
Source: Eur Respir J 2007; 30: Suppl. 51, 611s
Year: 2007

Clinical effectiveness of MDI-HFA-Modulite beclomethasone in the treatment of asthma – meta-analysis of randomized controlled trials
Source: Eur Respir J 2006; 28: Suppl. 50, 315s
Year: 2006

Clinical effectiveness of MDI-HFA-Modulite budesonide in the treatment of asthma – meta-analysis of randomised controlled trials
Source: Eur Respir J 2006; 28: Suppl. 50, 315s
Year: 2006

Inhaled budesonide in the treatment of early COVID-19 illness: a randomised controlled trial
Source: Virtual Congress 2021 – ALERT: bronchiectasis and COVID
Year: 2021



Efficacy and safety of single-inhaler triple therapy of glycopyrronium, formoterol and fluticasone in patients with COPD: a double-blind, randomised controlled trial
Source: ERJ Open Res, 7 (3) 00255-2021; 10.1183/23120541.00255-2021
Year: 2021



Nasal beclomethasone plus loratadine in patients with rhinitis and concomitant asthma: prospective, randomized, placebo-controlled trial
Source: Eur Respir J 2007; 30: Suppl. 51, 547s
Year: 2007